NBS

NeoStem, Inc

NeoStem, Inc. engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. The company also provides contract development and manufacturing services to clients advancing regenerative medicine product candidates in the regenerative medicine industry; adult stem cell collection and storage services; and therapy development utilizing T-cells for autoimmune and inflammatory conditions, including graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis, and solid organ transplant rejection. In addition, it engages in developing AMR-001, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow derived CD34+/CXCR4+ cells, which is in Phase II study for the treatment of damaged heart muscle; and researching and developing new therapies based on Very Small Embryonic-Like technology. It has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.